Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Quest Diagnostics ( (DGX) ).
At its May 20, 2026 annual meeting of stockholders, Quest Diagnostics shareholders elected all nominated directors to serve until the 2027 annual meeting, with candidates including Robert B. Carter, James E. Davis, Luis A. Diaz, Jr., M.D., and CEO Timothy C. Wentworth receiving majority support. Investors also approved an advisory vote on executive compensation and ratified PricewaterhouseCoopers as the company’s independent auditor for 2026, while a shareholder proposal seeking an independent board chair failed to gain sufficient backing, underscoring continued investor support for the existing leadership and governance structure.
These outcomes signal stability in Quest Diagnostics’ board composition and executive pay practices, suggesting shareholders remain broadly aligned with management’s strategy and oversight framework. The rejection of an independent chair proposal indicates investors are not yet willing to separate the roles of board leadership and executive leadership, maintaining the current governance model favored by the company’s leadership and potentially reinforcing continuity in strategic direction.
The most recent analyst rating on (DGX) stock is a Hold with a $220.00 price target. To see the full list of analyst forecasts on Quest Diagnostics stock, see the DGX Stock Forecast page.
Spark’s Take on DGX Stock
According to Spark, TipRanks’ AI Analyst, DGX is a Outperform.
Overall score is supported primarily by a strong and guidance-raising earnings outlook with robust volume/organic growth and expected margin expansion. This is balanced by only mid-level underlying financial statement strength (notable leverage and softer recent cash conversion) and mixed near-term technical momentum, while valuation looks reasonable rather than deeply compelling.
To see Spark’s full report on DGX stock, click here.
More about Quest Diagnostics
Quest Diagnostics operates in the diagnostic information services industry, providing laboratory testing, screening, and related health information services to physicians, hospitals, employers, and patients. The company focuses on delivering clinical lab testing and diagnostic insights that support medical decision-making and healthcare management in the U.S. and international markets.
Average Trading Volume: 903,007
Technical Sentiment Signal: Buy
Current Market Cap: $21.45B
See more insights into DGX stock on TipRanks’ Stock Analysis page.